Overview

Safety, Tolerability and Pharmacokinetics of FTX-6058

Status:
Recruiting
Trial end date:
2021-12-19
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety, tolerability and pharmacokinetics of FTX-6058 in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Fulcrum Therapeutics
Treatments:
Midazolam